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Abstract: Merkel cell carcinoma is an aggressive neuroendocrine skin cancer that usually 
affects elderly patients. Despite being uncommon, incidence has been steadily increasing over 
the last two decades, likely due to increased awareness, better diagnostic methods and 
aging of the population. It is currently one of the most lethal cutaneous malignancies, with a 
five-year  overall  survival  of  approximately  50%.  With  the  better  understanding  of  the 
molecular pathways that lead to the development of Merkel cell carcinoma, there has been an 
increasing excitement and optimism surrounding novel targeted therapies, in particular to 
immunotherapy. Some of the concepts surrounding the novel targeted therapies and currently 
ongoing clinical trials are reviewed here. 
Keywords: Merkel cell carcinoma; merkel cell polyomavirus; immunotherapy; targeted 
therapy 
 
1. Introduction 
Merkel  cell  carcinoma  (MCC)  is  an  uncommon  and  aggressive  neuroendocrine  skin  tumor  
thought  to  originate  from  the  Merkel  cells  of  the  basal  layer  of  the  epidermis  given  its  shared 
cytoplasmic  dense-core  neuroendocrine  granules  and  keratin  filaments  (cytokeratin-20)  expression 
characteristics [1,2]. It usually affects individuals in their 7th and 8th decades of life. Known risk 
factors include age older than 50 years, white skin, Merkel cell polyomavirus (MCV) infection, T-cell 
immune deficiency and ultraviolet exposure [3,4]. For those without distant metastasis at presentation, 
surgery with or without radiation therapy cure approximately half of them [5]. Unfortunately the other 
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half will develop disease recurrence and die of metastatic disease 1 to 2 years later, with only 18% of 
patients alive at 5 years [5,6]. MCC remains an orphan disease with no standard of care treatment for 
those with advanced disease. Because of the histologic and biologic similarities to small cell lung 
cancer, another high-grade neuroendocrine tumor, the same chemotherapeutic agents are commonly 
used  either  alone  or  in  combination.  Although  response  rates  reported  to  polychemotherapy  are  
60%–75%, median duration of response is only 8 months with a toxic death rate around 4%–7% for 
this patient population [7,8]. Newer, more effective and less toxic therapies are clearly needed. The 
recent discovery of a human polyomavirus (MCV) clonally integrated in MCC cells explains, at least 
partially, why patients with T cell deficiency have a higher risk of developing MCC when compared to 
the general population [4,9]. Rodig et al., utilizing a novel mouse monoclonal antibody (Ab3) with 
increased sensitivity for a MCV large T antigen fragment identified MCV in 97% of their samples, in 
contrast  to  81%  found  with  the  previously  described  murine  monoclonal  antibody  CM2B4  [10].  
This suggests that MCV in MCC is more common than previously reported. In fact, using improved 
polymerase chain reaction-based methods against both the large T and small T antigens, viral DNA 
was detected in 100% of the tumors tested, supporting the notion that MCV is a major contributor to 
the pathogenesis of MCC [10]. Despite the increased risk associated with immunosuppression, most of 
the newly diagnosed patients have no history of immune dysfunction, suggesting that tumor cells are 
capable of hiding and escape from the immune system [3]. Mechanisms of immune evasion include the 
tumor cell ability of ―immunoediting‖, down- and/or up-regulating molecules required for immune 
recognition and suppression, respectively [11]. This is supported by evidence that tumor cells from 
immunodeficient mice are more immunogenic than those from immunocompetent mice [11]. With a 
better  understanding  of  the  biology  of  this  disease,  significant  interest  has  risen  in  testing 
targeted/immune  therapies  in  MCC.  Here  we  review  the  rationale  for  therapies  currently  ongoing 
testing in MCC or underway. 
2. Cytotoxic Therapy 
Given the rarity of this disease and limited number of prospective trials, most of the data is obtained 
from a single institution, retrospective studies of small number of patients and meta-analysis. Commonly 
used agents include platinum, etoposide, anthracycline, cyclophosphamide, vincristine, bleomycin and 
5-fluorouracil  either  alone  or  in  combination.  No  randomized  studies  have  compared  different 
chemotherapy regimens and most of the studies evaluating chemotherapy have a mixture of patients 
with metastatic and locally advanced disease, where chemotherapy was used in the adjuvant setting. 
Voog et al. performed a literature review on chemotherapy for patients with MCC [7]. It was a very 
heterogeneous group with 107 (75 with distant metastasis) patients undergoing 42 different chemotherapy 
regimens.  Cyclophosphamide  or  ifosfamide-containing  regimes  were  given  to  60  patients  (56%), 
anthracycline-containing regimens to 53 patients (49%), platinum-containing regimens to 27 patients 
(25%), 5-fluorouracil-containing regimens to 14 patients (13%) and other regimens to 13 patients (12%). 
For those with metastatic disease, the objective response rate and median overall survival was 57% and 
9 months, respectively. Although response rates appeared to be better for cisplatin and adriamycin 
combination therapy, and 5-fluorouracil containing (versus non-containing) regimens, none was associated 
with  significantly  superior  survival.  In  addition,  16%  of  the  patients  aged  65  and  older  died  of Cancers 2014, 6  1182 
 
 
treatment-related toxicity. Interestingly, two out of 14 patients with metastatic disease who achieved a 
complete response after first line chemotherapy were still alive without evidence of disease 45 and 120 
months after the beginning of chemotherapy. Given the significant toxicity associated with  cytotoxic 
therapy for these patients, increased efforts should be made to identify those who will likely derive the 
most benefit from cytotoxic therapy and spare those unlikely to benefit from the toxicity related to it. 
3. B-Cell Lymphoma 2 (Bcl-2) 
Bcl-2  oncoprotein  blocks  programmed  cell  death  (or  apoptosis)  and  contributes  to  tumor  
growth [12]. Moll et al. compared Bcl-2 protein expression between Merkel cells and MCC, and 
demonstrated a higher and more homogeneous protein expression in tumors, suggesting a role of this 
anti-apoptotic protein in the pathogenesis of this disease [13]. Oblimersen sodium (G3139; Genasense, 
Genta Incorporated, Berkeley Heights, NJ, USA), a phosphorothionate antisense oligonucleotide that 
blocks  the  production  of  Bcl-2  protein,  was  tested  in  severe  combined  immunodeficiency  mouse 
xenotransplantation  model  for  human  MCC.  Results  were  very  encouraging  with  decreased  Bcl-2 
expression, increased apoptosis and reduction of tumor growth seen in those treated with oblimersen in 
comparison to control oligonucleotides or cisplatin [14]. This led to a multicenter phase 2 trial testing 
this agent in 12 patients with recurrent or metastatic MCC [15]. Results of this trial were disappointing 
revealing  no  objective  responses  and  stable  disease  in  only  3  patients.  In  an  attempt  to  evaluate 
differences in Bcl-2 expression between MCV positive and negative MCC, and correlate its expression 
with prognosis, Sahi et al. analyzed 116 MCC specimens with clinical data. Eighty-five percent of the 
MCC were Bcl-2 positive [16]. No significant difference in MCV DNA occurred between the Bcl-2 
positive and negative tumors. In contrast to what was previously thought, Bcl-2 negative tumors had 
more advanced stage at presentation and worse prognosis in contrast to Bcl-2 positive tumors. These results 
suggest that tumor progression may be due to mechanisms that are independent of Bcl-2. On another 
study, Lasithiotaki et al. evaluated the gene expression analysis of both MCV positive and negative 
non-small cell lung cancer samples [17]. Downregulation of Bcl-2 gene and increased expression of 
BRAF  gene and  its phosphorylation  were  seen in  MCV positive  samples  in comparison to MCV 
negative samples, further supporting the notion that other genomic abnormalities may contribute to the 
pathogenesis of MCV-related disease. 
4. KIT 
KIT (CD117), also known as mast/stem cell growth factor (SCF) receptor, is a proto-oncogene.  
Co-expression of KIT and its ligand stem cell factor has been reported in MCC suggesting an autocrine, 
ligand-dependent  activation  of  KIT  [18,19].  Experiments  with  MCC-1  cell  lines  demonstrated 
phosphorylation and activation of extracellular receptor kinase (ERK)1/2 and AKT in parallel with 
KIT autophosphorylation by SCF, leading to cell survival and proliferation [20]. Imatinib mesylate 
(Gleevec
®, STI-571, Novartis, Basel, Switzerland) is a small molecule tyrosine kinase inhibitor against 
bcr-abl, platelet-derived growth factor receptor (PDGFR) and KIT. The frequent expression of KIT in 
MCC led the Southwest Oncology Group to evaluate the activity of imatinib 400 mg orally daily in  
23  MCC  patients  [21,22].  Only  one  patient  had  a  partial  response  and  three  had  stable  disease.  
No complete responses were seen. The median progression-free survival and overall survival were one Cancers 2014, 6  1183 
 
 
month (95% CI: 1–2 months) and 5 months (95% CI: 2–8 months), respectively. DNA sequencing 
performed in only two patients (one non-responding and one with stable disease) revealed no KIT 
mutation. Other studies have confirmed the lack of KIT activating mutations in MCC which may explain 
the poor responses seen to imatinib therapy [18,23]. There is one case reported in the literature of a 
complete response in a patient with MCV positive-MCC after imatinib therapy [24]. It is unclear why 
this patient responded but an activating mutation in either KIT or PDGFR may have been present to 
explain that. 
5. Somatostatin Analogue 
Octreotide (Sandostatin, Sandoz Pharmaceuticals, Basel, Switzerland) is a biologically fully active 
octapeptide with structure and activities similar to those of the native hormone somatostatin. Somatostatin 
and analogues have been shown to inhibit angiogenesis and to have anti-secretory and anti-proliferative 
effects in both functional and non-functional tumors [25,26]. Pyronet et al. suggested that these effects 
may be mediated by different somatostatin receptors/signaling pathways, and on the specific target cell 
intracellular signaling [27]. A direct correlation between somatostatin receptor type 2 (sst2) protein 
expression and tumor response to octreotide therapy has been shown [28]. Expression of sst2 has been 
demonstrated in MCC [29], and long-lasting complete responses in patients with MCC expressing 
somatostatin  receptor  receiving  octreotide  analogues  have been  reported  [30,31].  A  phase  1, dose 
escalation study evaluating another somatostatin analogue, pasireotide (SOM230, Novartis) safety, 
pharmacokinetics,  and  anti-tumor  activity  in  patients  with  metastatic  disease  is  currently  ongoing 
(www.clinicaltrials.gov identifier number: NCT01652547) (Table 1). A peptide receptor radionuclide 
therapy  with  radiolabeled  somatostatin  analog  (177Lu-DOTATATE)  is  also  under  investigation  for 
somatostatin receptor-expressing neuroendocrine tumors (NCT01237457) (Table 1). 
Table 1. Clinical trials currently recruiting MCC patients. 
Clinicaltrials.gov 
identifier 
Phase  Investigational Agent  Targets/Mechanism of Action 
NCT02054884  2  F16-IL2 ±  Paclitaxel 
Tenascin-C vs. Microtubule  
disassembly inhibitor 
NCT02036476  2  Cabozantinib  VEGFR2, MET 
NCT01237457  2  177Lutetium-DOTA-Octreotide  Somatostatin Analogue 
NCT01440816  2  Intratumoral IL-12  Immune stimulation 
NCT02035657  1  GLA-SE  Toll-like Receptor 4 analogue 
NCT01652547  1  Pasireotide  Somatostatin Analogue 
NCT01758458  1  Adoptive immunotherapy  Autologus CD8 + Antigen-specific T cells 
NCT01375842  1  MPDL3280  Anti-PD-L1 Cancers 2014, 6  1184 
 
 
6. Survivin 
Survivin (or baculoviral inhibitor of apoptosis repeat-containing-5), encoded by the BIRC5 gene,  
is a member of the inhibitor of apoptosis family. Its expression in tumors correlates with metastatic 
spread,  tumor  invasiveness  and  poor  prognosis  associated  with  chemotherapy  resistance  [32,33]. 
Indeed, survivin nuclear expression in MCC has been correlated with an aggressive clinical course [34]. 
Survivin expression is induced by MCV large T antigen and is critical to MCC survival. Arora et al. 
demonstrated  a  seven-fold  increase  in  mRNAs  for  survivin  in  MCV-related  versus  non-related  
MCC [35]. Upon T antigen knockdown in several MCV-positive-MCC cell lines, both transcript and 
protein levels of survivin decreased, and knockdown of survivin resulted in cell death [36]. YM-155 
(or Sepantronium bromide), binds to interleukin enhancer binding factor 3 (ILF3), ultimately decreasing 
E2F1/2-mediated transcriptional activation of survivin [36]. Dresang et al. tested YM-155 in MCV 
positive-MCC xenografts in non-obese diabetic, severe combined immunodeficient–gamma interleukin-2 
receptor null mice [37]. The drug was shown to be cytostatic in three out of four xenografts and its 
efficacy was enhanced by extending the duration of treatment as well as by increasing the YM-155 
dosage. In addition, the degree of efficacy was cell line dependent [37]. Other survivin inhibitors are 
currently undergoing testing in both pre-clinical and clinical settings. Clinical trials evaluating the 
activity of these agents alone or in combination with cytotoxic therapy in MCC are eagerly expected. 
7. Antibody-Drug Conjugates (ADCs) 
ADCs were developed in an attempt to optimize intra-tumoral drug delivery while sparing non-targeted 
tissues from the drug-related toxicity. It consists of an antibody, a cytotoxic drug and a linker that 
attaches the two. Once the ADC binds to the antigen expressed on the tumor cell surface, it undergoes 
internalization through a process called endocytosis [38]. Once internalized, the ADCs are commonly 
delivered to lysosomes where the antibody is degraded and the cytotoxic agent is released to bind to its 
pharmacological target [38]. Two ADCs are currently marketed for cancer treatment: Brentuximab 
vedotin (SGN-35, Adcetris
®, Seattle Genetics and Millenium/Takeda, Cambridge, MA, USA), against 
cluster  of  differentiation  (CD)30  for  relapsed  Hodgkin  and  anaplastic  large  cell  lymphomas,  and 
Trastuzumab emtansine (TDM-1, Kadcycla
®, Genentech and Roche, South San Francisco, CA, USA) 
for  HER-2  positive  metastatic  breast  cancer  that  received  prior  taxane  and  trastuzumab  therapies. 
Many  other  ADCs are under clinical testing. Virtually all MCC express CD56, which makes it an 
attractive target [39]. Lorvotuzumab mertansine (BB-10901, IMGN901, Immunogen, Waltham, MA, 
USA) is a conjugate of the cytotoxic maytansinoid, DM1, and the CD56-binding antibody, lorvotuzumab. 
A phase 1 dose escalating trial with this conjugate was performed in solid tumors. Once the maximal 
tolerated dose was established, an expansion cohort was performed to assess this ADC in patients with 
relapsed or refractory small-cell lung cancer, ovarian cancer and MCC [40]. On a preliminary report, two 
out of 14 MCC patients achieved a complete response. Updated efficacy and safety data are pending. 
Further studies evaluating this compound in MCC are anxiously awaited. Cancers 2014, 6  1185 
 
 
8. Phosphoinositide 3-kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Pathway 
mTOR is a serine/threonine protein kinase of the PI3K-related kinase protein family. It regulates 
cell  growth,  proliferation,  motility,  survival,  protein  synthesis  and  transcription  [41].  Lin  et  al. 
demonstrated mTOR pathway activation and impaired autophagy in MCC cell lines and tumor tissues. 
Moreover, mTOR inhibition decreased cell proliferation and induced autophagy and cell death in human 
MCC cells [42]. Nardi et al. detected PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic 
subunit alpha) activating mutations in six out of 60 MCC tumors, and demonstrated sensitivity of MCC 
cell lines harboring PIK3CA mutations to PI3K pathway inhibitors [43]. These studies suggest that patients 
with PI3KCA mutant MCC may benefit from PI3K pathway inhibitors. Phase 1 clinical trials evaluating 
PI3K pathway inhibitors in refractory solid tumors are currently available and consideration should be 
taken to include MCC patients on these studies. 
9. Angiogenesis 
Vascular endothelial growth factor receptor (VEGFR) is a tyrosine kinase receptor involved in 
angiogenesis. VEGFR type 2 (VEGFR2) has been shown to be overexpressed in MCC and its overexpression 
has been correlated with worse outcome [44,45]. A single case has been reported in the literature 
demonstrating activity of Pazopanib (Votrient
®, GlaxoSmithkline, Brentford, UK), an oral multikinase 
inhibitor against VEGFR, PDGFR and KIT, in a patient with metastatic MCC that progressed after 
cytotoxic therapy [46]. A 1432T > C mutation in PDGFR-α (ser478pro) gene was found in three tumor 
samples (this patient and two others with MCC), as well as in their germline DNA. A previous study 
has also identified that single heterozygous base change in exon 10 of the PDGFR gene in 3 of 9 MCCs, 
suggesting this may be an activating mutation and possibly a predictive biomarker for tyrosine kinase 
inhibitors [47]. Cabozantinib (Cometriq
®, XL-184, Exelixis, South San Francisco, CA, USA) is an oral 
multikinase inhibitor preferentially against VEGFR2 and c-MET (mesenchymal-epithelial transition 
factor). It was recently approved for treatment of patients with progressive, metastatic, medullary thyroid 
cancer (another neuroendocrine tumor) after a phase 3 clinical trial demonstrated an improvement in 
the median progression-free survival compared to placebo (11.2 months versus 4 months, p < 0.001) [48]. 
MCC is known to overexpress paired box gene 5 (PAX-5), which controls c-MET [49]. Synergistic 
effects have been demonstrated with dual VEGFR2/c-MET inhibition [50]. A phase 2 trial evaluating 
the activity of cabozantinib in MCC is currently recruiting patients (NCT02036476) (Table 1). 
10. Immunotherapies 
10.1. Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4, CD152) 
CTLA-4 is a member of the CD28 family of receptors and ligands. The CD28 family contains a 
number of immunological checkpoints to attenuate the immune response caused by an inflammatory 
process (e.g, infection or neoplastic) and protects collateral tissue damage [51]. CTLA-4 is found  
on the surface of T cells, inhibiting its activation. Both CTLA-4 and CD28 share the same ligands:  
CD80 and CD86, which are present in antigen presenting cells and the T cells themselves. CTLA-4 
counteracts the co-stimulatory activity of CD28 by competing for binding and its higher affinity for  Cancers 2014, 6  1186 
 
 
the shared ligands. Genetic ablation of CTLA-4 results in profound lymphoproliferation, particularly 
of the CD4
+ T cells [52]. A phase 3 trial evaluating ipilimumab, a fully human monoclonal antibody 
against CTLA-4, in metastatic melanoma, resulted in prolonged overall survival compared to a peptide 
vaccine against the melanosomal gp100 antigen [53]. Based on these results, ipilimumab was approved 
for treatment of patients with metastatic melanoma. Importantly, 15% of the patients developed grade 
3–4 toxicity, mostly immune-related, and death in seven patients [53]. A dense lymphocytic infiltrate of  
T-cells has been reported in cases of spontaneous regression of MCC after biopsy, strengthening the 
hypothesis of an immune-mediated process in the pathogenesis of MCC [54,55]. Moreover, Paulson et al. 
have demonstrated that intratumoral infiltration of CD8
+ lymphocytes and lack of systemic immune 
suppression are independent predictors of improved survival among MCC patients [56,57]. Clinical 
trials testing anti-CTLA-4 in MCC are eagerly expected, and risks/benefits should be carefully weighted 
on this patient population given the drug-related toxicity previously reported. For unclear reasons, a 
phase  2  trial  evaluating  the  activity  of  ipilimumab  in  patients  with  metastatic  MCC  was  recently 
withdrawn prior to initiation of patient accrual (NCT01913691). 
10.2. Programmed Death 1 (PD-1) 
PD-1 is another T-cell co-inhibitory receptor of the CD28 family of receptors and ligands. It is 
expressed in T cells, B cells and NK cells, upon activation, and has 2 ligands: PD-L1 is expressed in 
both hematopoietic (B, T, myeloid and dendritic cells) and non-hematopoietic cells, and non-lymphoid 
organs; PD-L2 is expressed in antigen presenting cells (macrophages and dendritic cells) and more 
recently was found to be expressed in T cells [58,59]. Engagement of PD-1 with its ligands, inhibits T-cell 
receptor signaling and dowregulates the expression of anti-apoptotic molecules and pro-inflammatory 
cytokines  [59].  Upregulation  of  PD-L1in  peripheral  tissues,  in  response  to  immune  stimulation 
(interferon-γ), protect them against the collateral damage caused by the activated T-cells [60]. PD-1  
is expressed by a large proportion of tumor-infiltrating lymphocytes (TIL) [61]. PD-L1 is expressed  
in many tumors and its expression correlates with poor prognosis [62]. Indeed, Taube et al. described 
increased expression of PD-L1 in melanoma cells immediately adjacent to TILs while tumors with 
minimal TIL infiltration were less likely to express PD-L1, suggesting that tumor cells protects themselves 
against  immune-mediated  destruction,  at  least  partially,  by  inactivating  effector  T  cells  through  
PD-1/PD-L1 engagement [63]. Results of a phase 1 clinical trial evaluating anti-PD-1 in 296 patients 
with refractory solid tumors, revealed disease responses in melanoma (28%), renal cell carcinoma 
(27%) and in non-small cell lung cancer (18%) [64]. Thirty-six percent of the patients with PD-L1 
expression responded in contrast to none without it. Grade 3-4 immune-related events occurred in 6% 
of the patients, with fatal pneumonitis seen in 3 cases. Afanasiev et al. demonstrated that circulating 
MCV-specific CD8 T cells and MCC-infiltrating lymphocytes express higher levels of PD-1 compared 
to T cells specific to other human viruses [65]. As seen in melanoma, higher PD-L1 expression was 
correlated with TIL infiltration, suggesting that anti-PD-1/PD-L1 inhibitors may be a therapeutic rationale 
for these patients [65]. In another study, Lipson et al. analyzed 49 tumors and demonstrated PD-L1 
expression in 50% of the MCV positive- and none in the MCV negative-MCCs [64]. In addition, PD-L1 
expression correlated with CD8
+ TILs and it was shown to be a positive prognostic factor, again 
suggesting that enhancing the immune response with PD-1/PD-L1 blockade may prove to be a successful Cancers 2014, 6  1187 
 
 
therapy for these patients [66]. A multicenter phase 1 clinical trial testing MPDL3280A (Genentech),  
a human monoclonal antibody against PD-L1, in refractory solid and hematologic malignancies, including 
MCC is currently recruiting patients (NCT01375842) (Table 1). 
10.3. Adoptive Immunotherapy 
Adoptive  immunotherapy  involves  the  process  of  isolating  TILs  or  virus-specific  lymphocytes, 
expansion of these cells in the lab and infusion of the autologous lymphocytes back to the patients. 
Rosenberg et al. described durable complete responses in 93 heavily pretreated patients with metastatic 
melanoma using T cell transfer immunotherapy [67]. Lymphocytes from resected metastatic melanoma 
lesions were grown in the lab with high-dose interleukin(IL)-2. Prior to receive TIL infusion, all patients 
received a non-myeloablative lymphodepleting regimen with or without total body irradiation (TBI) 
and autologous stem cell transplant. Overall response rate was 56%; 22% of the patients achieved a 
complete response (CR). Three- and five-year survival rates were 36% and 29%, respectively, with 93% of 
those in CR alive in 5 years. On another study, 10 patients with Epstein-Barr virus (EBV)-positive poorly 
or undifferentiated nasopharyngeal carcinoma (4 with high risk of relapse and 6 with relapsed/refractory 
disease) underwent adoptive transfer of cytotoxic T lymphocytes specific for the EBV antigens [68]. 
Two out of six patients with resistant or refractory disease had complete and sustained remissions, one had  
a partial response and another one stable disease. The four patients who were in remission at the time of 
the infusion, remained disease free after 19 to 27 months. Treatment was well tolerated. Lyngaa et al., 
through a high-throughput flow cytometry-based platform developed for T-cell epitope identification, 
characterized MCV-specific CD8 T-cell epitopes in large T antigen, small T antigen and polyomavirus 
capsid protein 1 (VP1) [69]. Although T cells recognizing the MCV-encoded VP1 were present in both 
MCC patients and healthy donor, T-cell responses to the oncogenic proteins large and small T antigens 
were exclusively detected in MCC patients, representing ideal targets for immunotherapy. Indeed, large T 
antigen-specific CD8 T cells effectively killed MCV positive-MCC cell lines [69]. A phase 1/2 trial is 
currently investigating this approach in metastatic MCC (NCT01758458) (Table 1). 
10.4. Intratumoral Therapy 
Electrocorporation is the process that utilizes an electric charge to facilitate the entry of macromolecules 
(chemotherapy or immunotherapy) into the cell. Results of a phase 1 dose escalation trial evaluating 
IL12 plasmid electrocorporation in 24 patients with metastatic melanoma have been reported [70]. 
Treatment was well tolerated with no dose limited toxicities identified. Interestingly, two out of 19 patients 
developed complete regression of all metastasis, including those untreated, without any other systemic 
therapy  administered, suggesting a  systemic effect. Eight additional patients  had stable disease  or 
partial response. A phase 2 clinical trial testing this therapy in metastatic MCC is currently ongoing 
(NCT01440816) (Table 1). 
10.5. F16-IL2 
The  immunocytokine  F16-IL2  consists  of  the  human  monoclonal  antibody  F16  specific  to  the 
extradomain A1 of tenascin-C fused to human IL2 [71]. Tenascin-C is part of the stroma of most solid Cancers 2014, 6  1188 
 
 
cancers, and plays a role in enhancing proliferation, invasion and angiogenesis during tumorigenesis 
and metastasis [72]. Marlind et al. tested its therapeutic performance with and without chemotherapy 
in a human breast cancer xenograft model [71]. When used as monotherapy, F16-IL2 had a superior 
therapeutic benefit compared with unconjugated recombinant IL2. When F16-IL2 was combined with 
low and high dose paclitaxel or high (but not low) dose doxorubicin, a synergistic effect was demonstrated 
with  a  dramatic  increase  of  survival  time  observed  when  compared  to  single  agent  therapy  [71]. 
Pedretti et al. conducted a similar study evaluating the therapeutic activity of F16-IL2 and temozolamide 
(alone or in combination) in murine models of subcutaneous and intracranial glioblastoma [73]. In  
the subcutaneous model, monotherapy with F16-IL2 led to minor tumor growth retardation. Despite  
a strong tumor regression seen on the temozolomide group, response duration was short. By contrast, 
mice treated with the combination therapy underwent complete remission 40 days after beginning of 
therapy, and remained disease free for over 160 days. In the intracranial model, the combination treatment 
was also more efficacious, resulting in 73% decrease in tumor volume 25 days after the start of treatment, 
as well as in longer survival of the animals. In both xenograft models, there was a selective accumulation 
of F16-IL2 around tumor vascular structures, and the recruitment of immune effector cells into the 
tumor lesions, but not in normal organs of the same mice [73]. A phase 2 randomized trial is currently 
testing F16-IL2 with or without paclitaxel in patients with metastatic MCC (NCT02054884) (Table 1). 
11. Glucopyranosyl Lipid Adjuvant-Stable Emulsion (GLA-SE) 
GLA-SE is a toll-like receptor (TLR)4 agonist. TLR agonists mimic pathogens, stimulating dendritic 
cells to produce T helper 1 cell-promoting cytokines, tumor necrosis factor-α (TNF-α), IL1β, IL6  
and IL12 [74]. Maturation of dendritic cells by TNF-α is required for activation of both T helper cells 
and cytotoxic T lymphocytes [75]. IL12 increases interferon-γ production, augmenting T helper-1 cell 
response [76]. In an attempt to enhance the T helper 1 cell-mediated cytotoxic T lymphocytes response 
to influenza virus, Behzad et al. combined GLA-SE to split-virus vaccines to stimulate peripheral 
blood  mononuclear  cells  of  adult  patients  in  vitro,  and  then  challenged  them  with  live  influenza  
virus [77]. Results were very promising with activation of myeloid dendritic cells, producing high 
levels of T helper 1 cells-promoting cytokines, and increased interferon-γ:interleukin-10 ratio and the 
cytolytic response to influenza virus challenge. Based on these effects, a phase 1 feasibility study is 
currently testing GLA-SE in MCC patients (NCT02035657) (Table 1). 
12. Conclusions 
Significant progress has been made on the understanding of MCC pathogenesis since the identification 
of a clonal integration of a human polyomavirus in MCC approximately 5 years ago [3]. Different 
mechanisms of immune system evasion and new targeted therapies have been identified promoting 
significant excitement for those who manage this aggressive disease. To date, MCC remains an orphan 
disease. Cytotoxic agents are still considered first line therapy for those with metastatic disease despite 
the toxicity associated with it and the palliative intent of therapy. Patients should be encouraged to enroll in 
clinical trials with the hope that newer therapies will change the outcome of this devastating disease. 
Although immunotherapy trials are not an option for those immunosuppressed, the anti-angiogenesis, 
PI3K/mTOR inhibitors and somatostatin analogue trials are. Providers should not hesitate to refer patients Cancers 2014, 6  1189 
 
 
for phase 1 trials, even as first line therapy, if there is a good rationale to test that drug for this disease. 
As noted above, preliminary results of a phase 1 trial with lorvotuzumab in refractory solid tumors 
revealed complete responses in 2 metastatic MCC patients. Finally, it is important to remember that 
MCC is a radiosensitive disease and radiation therapy should be considered for patients with symptomatic 
metastatic or recurrent disease. 
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